Also known as: Lys-Pro-Val (alpha-MSH fragment)
The anti-inflammatory tail end of alpha-MSH, used mainly for gut and skin inflammation.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Enters cells through the PepT1 transporter in the gut lining and blocks NF-kB inflammatory signaling.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Gut health | D | Animal or cell studies only |
| Skin, hair & appearance | D | Animal or cell studies only |
| Immune & infections | D | Animal or cell studies only |
At a glance
- Route
- Oral, subcutaneous, or topical
- Half-life
- Short
Reported dosing
200 to 500 mcg daily, oral for gut, injected for systemic use (practitioner reports).
Timing: Oral on an empty stomach.
Cycle: 4 to 8 weeks.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Few reported
Who should avoid it
- Pregnancy (no data)
Often combined with
With BPC-157 for gut repair.
Key findings
Reduced colitis in mouse studies. No published human trials.
2026 update
Apr 2026: moved off the Category 2 list. Jul 2026: advisory committee voted 8-6-1 for compounding; FDA decision pending.
Where it is legal (Oct 2026)
| US | Pending |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open KPV in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.